Back to top
more

Integer Holdings (ITGR)

(Delayed Data from NYSE)

$132.43 USD

132.43
322,778

+3.19 (2.47%)

Updated Oct 14, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Here's Why You Should Hold On to Baxter (BAX) Stock Now

Baxter's (BAX) cyclophosphamide performance continues to remain dismal. Nevertheless, the company witnesses positive tidings of other products on the regulatory front.

    Why Integer (ITGR) is a Top Pick for Momentum Investors

    Does Integer (ITGR) have what it takes to be a top stock pick for momentum investors? Let's find out.

      Amedisys Ties Up With Medalogix to Boost Home Health Unit

      Amedisys (AMED) pursues deals to boost Home Health business.

        Cooper Companies (COO) Earnings Miss & Revenues Beat in Q3

        Cooper (COO) gains from solid CSI revenues in Q3; international revenues surge.

          Here's Why You Should Invest in Veeva (VEEV) Stock Right Now

          Strong fundamentals and a solid Q2 aid Veeva (VEEV).

            Glaukos (GKOS) Jumps: Stock Rises 7.2%

            Glaukos (GKOS) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

              Illumina MiSeq Dx Okayed in China, NGS Platform Gets a Boost

              Illumina's (ILMN) receipt of CNDA approval for MiSeq Dx Sequencing System is expected to expand customer base and boost the top line.

                Here's Why You Should Invest in Phibro (PAHC) Right Now

                Phibro (PAHC) sees improvement across all segments. The Animal Health business has been a key contributor.

                  Patterson Companies (PDCO) Misses Q1 Earnings Estimates

                  Patterson Companies' (PDCO) adjusted earnings declines considerably on a year-over-year basis in Q1. Lackluster performance by the dental unit is a concern.

                    Here's Why You Should Buy Inogen (INGN) Stock Right Now

                    Inogen (INGN) gains from strong Q2 results and bright global prospects.

                      Here's Why You Should Invest in Genomic Health (GHDX) Now

                      Genomic Health (GHDX) gains ground on growing adoption of prostate cancer test and solid international scenario.

                        Ecolab's Nalco Pairs With XOS to Boost Global Energy Unit

                        Ecolab's (ECL) Nalco Champion's 3D CRUDEFLEX will integrate XOS' Clora Online; market prospects bright.

                          Here's Why You Should Hold On to Stryker (SYK) Stock Now

                          Challenging global economic conditions and supply-side issues are major deterrents to Stryker's (SYK) top line in the near term. The company's significant exposure to robotics is a positive.

                            New Buyouts Aid Boston Scientific Amid Dull Pacemaker Sales

                            Boston Scientific (BSX) continues to adopt organic as well as inorganic routes for success. However, sluggish global pacemaker sales continue to disappoint.

                              Phibro Animal (PAHC) Q4 Earnings Beat, Sales Improve Y/Y

                              Phibro (PAHC) witnesses year-over-year improvement across all segments in Q4.

                                Wright Medical Buys Cartiva to Boost Lower Extremities Unit

                                Wright Medical's (WMGI) addition of Synthetic Cartilage Implant is likely to drive revenues in 2019; raised guidance for 2018 encourages.

                                  Here's Why You Should Hold On to DexCom (DXCM) Stock Now

                                  DexCom (DXCM) is expected to benefit from lucrative prospects in the diabetes market. However, the company's margins were under pressure in the last reported quarter.

                                    STERIS (STE) Strategic Growth Strong, Competition a Woe

                                    STERIS' (STE) beneficial underlying market trends along with new product and service offerings are impressive. Meanwhile, the company worries over facing a severe competition.

                                      Bruker to Expand Molecular Diagnostics Arm With Hain Buyout

                                      Hain's molecular diagnostics solutions of bacterial and viral infections are expected to compliment Bruker's (BRKR) MALDI Biotyper and IR Biotyper microbiology platforms.

                                        Omnicell Patient Engagement Unit to Aid Medication Adherence

                                        Omnicell's (OMCL) revamped Patient Engagement platform likely to aid core Medication Adherence Unit; market looks promising.

                                          Here's Why You Should Invest in Integer (ITGR) Stock Now

                                          Integer Holdings (ITGR) gains on strong quarterly performance. The company is likely to gain from the Cardio & Vascular, Neuromodulation and Non-Medical Electrochem markets.

                                            Cerner, Duke Clinical Research Launch Risk Calculator App

                                            Cerner (CERN) launches new Risk Calculator app that will check cardiac risk. The company's relentless efforts to digitize its EHR systems is commendable.

                                              Medtronic (MDT) Grows on CRHF Arm, Margin Pressure Ails

                                              Solid demand for Medtronic's (MDT) quadripolar cardiac resynchronization therapy-pacemakers (CRT-P) along with growth in Mechanical Circulatory Support drives Heart Failure division revenues.

                                                Hill-Rom (HRC) Touches 52-Week High: What's Driving It?

                                                Hill-Rom (HRC) rides high on impressive Q3 results along with increased focus on product innovation through research and development.

                                                  Veeva Systems (VEEV) Q2 Earnings & Revenues Beat Estimates

                                                  Veeva Systems (VEEV) gains from its flagship Vault platform. Also, expanding margins are an added positive for the company.